Table 1.
Baseline Characteristics of Patients.
| Patient characteristics | No. of patients (%) or mean±SD (n=73) | |
|---|---|---|
| Women | 58 (79) | |
| Age, y | 76.2±8.0 | |
| Body mass index; BMI, kg/m2 | 23.6±3.5 | |
| Systolic blood pressure; sBP | 132.5±17.8 | |
| Diastolic blood pressure; dBP | 74.1±9.9 | |
| Bone mineral density (young adult mean; YAM) (%) | ||
| Lumbar spine | Male 95.9±23.8, Female 82.0±17.3 | |
| Hip | Male 85.0±23.0, Female 73.4±14.1 | |
| Disease history | ||
| Cerebrovascular disease | 4 (5.4) | |
| Cardiovascular disease | 10 (14) | |
| Complications | ||
| Hypertension | 52 (71) | |
| Dyslipidaemia | 42 (58) | |
| Diabetes mellitus | 18 (25) | |
| Chronic kidney disease | ||
| Stage G1 | 8 (11) | |
| Stage G2 | 35 (48) | |
| Stage G3a | 18 (25) | |
| Stage G3b | 10 (14) | |
| Stage G4 | 2 (2.7) | |
| Osteoporosis | 33 (45) | |
| Regular alcohol consumption | 6 (8.2) | |
| Drug used | ||
| Calcium channel blocker | 40 (45) | |
| Angiotensin-converting enzyme inhibitor | 1 (1.4) | |
| Angiotensin II receptor blocker | 42 (58) | |
| β-blocker | 5 (6.8) | |
| Diuretic | 17 (23) | |
| Statin | 39 (53) | |
| Dipeptidyl peptidase-4 inhibitor | 6 (8.2) | |
| Antiplatelet drug | 14 (19) | |
| Bisphosphonate | 5 (6.8) | |
| Active vitamin D3 | 12 (16) |